-
1.发明公开公开(公告)号：US20230277598A1
公开(公告)日：2023-09-07
申请号：US18179212
申请日：2023-03-06
发明人： Santosh KESARI , Thomas ICHIM , Timothy Dixon , Kalina O'CONNOR , Wais KAIHANI , Duncan HUNTER
摘要： Disclosed are means, treatments and compositions of matter useful for treatment of chemotherapy/radiotherapy associated cognitive dysfunction. In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse cognitive dysfunction associated with chemotherapy and/or radiation therapy. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of neuroregeneration directly or indirectly.
-
公开(公告)号：US20230301938A1
公开(公告)日：2023-09-28
申请号：US18106925
申请日：2023-02-07
发明人： Thomas ICHIM , Timothy G. DIXON
IPC分类号： A61K31/09 , A61K31/122 , A61K31/26 , A61K36/71 , A61K36/82
CPC分类号： A61K31/09 , A61K31/122 , A61K31/26 , A61K36/71 , A61K36/82
摘要： Disclosed are means and methods of treating cognitive dysfunction associated with COVID-19 and/or other associated with inflammatory conditions. In one embodiment treatment of COVID-19 cognitive dysfunction performed by administration of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor cells and/or protect cells from inflammatory damage. In one embodiment said nutraceuticals are comprised of green tea extract, and/or nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiments nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.
-
搜索结果
2 条记录 (耗时 0.012 秒)
